News

IMR-687 Receives FDA Fast Track & Rare Pediatric Disease Designations for the Treatment of β-Τhalassaemia

IMR-687 Receives FDA Fast Track & Rare Pediatric Disease Designations for the Treatment of β-Τhalassaemia

IMARA Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin, announced the U.S. Food and Drug…
Coronavirus Pandemic: How Close Are We to a Vaccine?

Coronavirus Pandemic: How Close Are We to a Vaccine?

Researchers around the world are racing to develop a vaccine against Covid-19, with more than 140 candidate vaccines now tracked by the World Health Organization (WHO). Vaccines normally require years of testing…
”Blood Transfusion in Thalassaemia”: Save the Date for the Next TIF Webinar for Medical Specialists

”Blood Transfusion in Thalassaemia”: Save the Date for the Next TIF Webinar for Medical Specialists

TIF´s brand new Webinar, entitled ”Blood Transfusion in Thalassaemia” and organised as part of the eThalED Course, will be held on Monday, 31 August 2020, 15:00-16:00 EEST / 13:00-14:00 BST.…
TIF Publishes its Annual Report for 2019

TIF Publishes its Annual Report for 2019

This Annual Report showcases the Federation’s intensive efforts that took place in 2019 with the aim to ensure equal access to quality healthcare for every patient with thalassaemia and haemoglobin…
Viral Hepatitis & Thalassaemia: Q&A with Prof. John Koskinas

Viral Hepatitis & Thalassaemia: Q&A with Prof. John Koskinas

On the occasion of today´s World Hepatitis Day and with the aim of informing and raising awareness among patients with thalassaemia – and not only – about viral hepatitis that…
Novartis sickle cell drug Adakveo put on path to EU approval

Novartis sickle cell drug Adakveo put on path to EU approval

Novartis announced last Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending conditional marketing authorization of Adakveo® (crizanlizumab)…
”Liver Disease & Thalassaemia”: En route to the 3rd TIF Webinar for Medical Specialists

”Liver Disease & Thalassaemia”: En route to the 3rd TIF Webinar for Medical Specialists

Tune in for TIF’s upcoming webinar on ”Liver Disease & Thalassaemia” for Medical Specialists, organised in the context of our eThalED Course on Friday, 31 July, EEST 15:00-16:00. Prof. Geoffrey Dusheiko, Emeritus…
WORLD HEPATITIS DAY 2020: Towards a ”Hepatitis-free Future”

WORLD HEPATITIS DAY 2020: Towards a ”Hepatitis-free Future”

World Hepatitis Day is commemorated each year on 28 July to enhance awareness of viral hepatitis, an inflammation of the liver that causes a range of health problems, including liver…
Oxford vaccine: Early Trials Show Promising Results that Suggest “Double Protection” from Coronavirus

Oxford vaccine: Early Trials Show Promising Results that Suggest “Double Protection” from Coronavirus

The experimental vaccine being developed by AstraZeneca and Oxford University against the new coronavirus produced an immune response in early-stage clinical trials, data showed on Monday, preserving hopes it could…
Back to top button
Close
Close